Member Info for Bluelight

Monty on the 6th September you posted the same wrong numbers, and multiple investors highlight you were incorrect and gave you the actual numbers. On a down morning you pop up again with the same crap. You are not invested here, and what is worse you are trying to post misinformation to try to upset people for you own gains. Reported.

Thats a very narrow view there Blue83. The UK is not NCYT's only market. Where does it state that our goal is to produce an LFT to sell solely in the UK? If you look into it you can see that their strategy is clearly to sell their LFT alongside their PCR offerings to offer a complete package of products to it's wide range of global distributors, not sell to the UK gov. In Europe for example LFT's are not free, an indivdual has to buy them privately mostly. I imagine selling them to the UK gov is the last thing on their mind. Many posters seem obsessed with the UK, as though it is our only market. people need to look at the bigger picture. If this were the likes of ODX or AVCT of god forbid GDR I'd be worried about their sales offerings as they are all pinning their hopes on the UK gov. We've got stung by then and are wisely focusing on the global private market. Anyway, Im out on the lash, but final thought for the day. Why are we one of the only covid test producers that are making consistant strong sales, and on the flip side why are others not, and why therefore is that not highlighted in the NCYT shareprice. Quiet before the storm folks. Food for thought for all you fence sitters out there.

Leaves us as a truely stunning acquisition for somebody...

What Kitzie means is that the horse has already bolted, banging on about it isn't going to put the horse back in the stable. The price already more than reflects the issue, so whilst its obviously an important factor as to why we are where we are, its not relevant for day to day moves. The price will spike when it is concluded, but for now we can only focus on new developments such as new distributors, markets, acquisitions/takeovers etc. Banging on about an issue known for over 6m is pointless.

Yep, it's being controlled pretty well at the moment. Open it down a percent or two, grind along most of the day, end with little change to slightly down. All good and well, but it kills volume, which isn't great for market makers. Excitement and volatility drive their profits. No one really profits from this kind of a market. Patience though, these phases come and go.

Indeed flu is a fair comparison. Look how big the industry is around flu....

It's dangerous comparing disease mortality. If you look it another way, 7m uk people didnt catch cancer in one year like covid did, and you don't have a high chance of catching cancer by just buying food at your local supermarket, or by getting a pint. It's so dangerous because you can catch a potentially life threatening illness just by going about your day to day life. To dumb it down by saying it kills less than x or y is a dangerous thing to do

Ah Monty, if you were heavily invested you'd have done at least some minimal research. Revenue excluding DHSC is c£10m a month, with £100m (exc DHSC) as the guidance for the full year. Not £5m for 6 months, it's £10m a month. You really should research companies you invest in, even if its the most cursory of glances....

Yeah I view rainbow chasers as those that want massive returns quickly. For example those that invest in bitcoin stocks. Nothing wrong with having a long term higher target, if people didnt then why would anyone invest long term in AIM, there's no dividends mostly, so unless youve got a chance of a great share price return why bother. If you wanted to make 10-20% you could do that investing in the likes of BP with very little risk.

I disagree their covid. I dont think their are many rainbow chasers here at all, mostly long term investors (either through choice or because of the drop). Many rainbow chasers appear when we get some upwards momentum, you see a huge number of new faces appear for a day or two, then dissapear. Some of the other plays however are virtually only owned by rainbow chasers, naming no names on said companies.

I find it funny how often investors in companies claim that their company is 'best in class', and 'selling everything they can produce'. It seems highly correlated that the more a share is a rainbow chase, the more its the best thing since sliced bread. Getting back to reality, there are very few companies that have made money from covid, the Chinese, NCYT, and a couple of others mostly. You could count the sales from the other covid rainbow stocks on one hand, and I'm not talking one finger = 1 million, I'm talking one finger = 1 pound (or minus in most cases). That said they are rainbow chasing for a reason, logic doesn't play a part of it.

Yep nothing to worry about, whats 50k a day known infections, and 1000 people a day hospitalised worth worrying about... Oh and thats just the UK of course. There's a very distinct media attempt to dampen the stories around it, and I imagine many people think its bascially tailing off. That is a very consicious attempy by the gov to control the sentiment on it. Good luck to them when autumn/winter kicks in. In the meantime, testing at record highs and expanding, money in the bank for NCYT.

The market has always assumed covid will end soon, however its not slowing time at all. Initially it was here for a month or two, then winter, then it's definitely be gone last summer, now next summer or winter.... There in lays the opportunity to make money here. You can invest in a share that makes min 10m a month and growing, with no end in sight, or you can read bbc news and listen to the government and assume covid is over. I know where my money is.

Because it is incredibly easy to control the direction on very little volume. Traders are only interested when its spiking up 50% in a day or two, in the meantime they just hold off or stay of the short side. It's dull, but for those with funds its a good opportunity to take advantage of it.

I think they tried by appointing Numis and by appointing Oddo. Unfortunately in Oddo they chose a broker that bascially stole a fee, trashing NCYT whilst at the same time bringing no II investment in. If we are 75% French held there's should have been the role of lead broker driving us forwards. Instead they acted as a weight around our necks, and I'd argue acted against NCYT's interests. Still not clear if we have binned them or not, but they have been noticeably quiet, and not involved in our coms. A good step would be to replace them with a more well respected useful broker who works for the company. A US broker would be a good sign.

Spoken like a true school teacher Starbright, that has put us all in our place....

Renumeration when we all succeed, all for that. Renumeration as a matter of course (which to me appears how the resolutions currently look) certainly not. It's pretty ballsey to try to get a director payout when many investors are down 70-80%. Be great if they got paid in direct correlation to the share price each month, then their minds would most certainly be focused

I look at business in a pretty straightforward way. If you suceed you should be rewarded, however if you fail then you should not receive any benefits, in fact where possible they should be clawed back. If I failed in my job I wouldn't receive share options or additional renumeration, most are the same. From an investors point of view this year has been a total failure. True, they'll probably turn it around but as we stand today they have failed this year, and as such I wont be voting 'For' for anything that is not simply a regulatory necessity. I'm hoping if they get enough against votes then it might open their eyes to taking some supportive measures for investors, something tangible not simply words.

Just went through it. Basically i'm for any of the publication of info, reports etc, but I'm against any director renomination or renumeration in whatever form to the company or its employees.

If they turn it around (which I think they will, fundamentals shine through in the end) then they'll get my backing on renumeration. For now though its a no from me. Bit unrealistic to expect your investors to agree to future potential payments to the company if at the same time your majority of investors are losing money. A majority no might highlight to them the need for creating a return to investors. We've had the words about returning long term investor value, but not the actions. No additional renumeration agreement from me until I see evidence of that first.